Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study.
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2017
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms AURA
- Sponsors AstraZeneca; Takeda
- 07 Jun 2017 Biomarkers information updated
- 11 Sep 2013 Pooled analysis presented at the 23rd Annual Congress of the European Respiratory Society.
- 07 May 2012 Additional company (Takeda Global Research and Development Center) added in association as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History